Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Unjha Formulations Ltd
Your Vote -
Buy
50.00%
Hold
0.00%
Sell
50.00%
50.00%
2 users have voted
Option Chain
Analyzes market sentiment, predicts Unjha Formulations Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Unjha Formulatio - Filing Of Distribution Schedule
-
Unjha Formulatio - Cash Flow Statement For The Year Ended 31.03.2025
-
Unjha Formulatio - Intimation Under Regulation 30 Read With Part A Of The Schedule III Of SEBI (Listing Obligations And Discl
-
Unjha Formulatio - Regulation 44(3) Of The SEBI (Listing Obligation And Disclosure Requirements) I.E. Voting Results
-
Unjha Formulatio - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
-
Unjha Formulatio - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
-
Unjha Formulatio - Shareholder Meeting / Postal Ballot-Outcome of AGM
-
Unjha Formulatio - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
-
Unjha Formulatio - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
-
Unjha Formulatio - Publish Un-Audited Financial Results For The Quarter Ended As On 30/06/2025
-
Unjha Formulatio Q1 net profit down 44.29% at Rs 0.39 cr
-
Unjha Formulatio - Approval Of Un-Audited Financial Results Of The Company For First Quarter Ended On 30Th June ,2025 And
-
Unjha Formulatio - Board Meeting Outcome for Approval Of Un-Audited Financial Results Of The Company For First Quarter Ended
-
Unjha Formulatio - E- Voting Facility At The Forthcoming Annual General Meeting & Intimation Of Fixation Of Cut-Off Date
-
Unjha Formulatio - Board Meeting Intimation for Board Meeting - Date: 06.08.2025( Un-Audited Financial Results For The Quarte
-
Unjha Formulatio - Regulation 47 Of SEBI(LODR) Regulations 2015.Published Notice Of AGM
-
Unjha Formulatio - Regulation 30 & 34(1) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
-
Unjha Formulatio - Reg. 34 (1) Annual Report.
-
Unjha Formulatio - Notice Of 31St Annual General Meeting Of Company\r\n\r\n
-
Unjha Formulatio - News Paper Advt. For 31St Annual General Meeting
-
Unjha Formulatio - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Unjha Formulatio has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2025
-
Unjha Formulatio - REGULATION 42(2) Of SEBI LODR,REGULATIONS 2015
-
Unjha Formulatio - Intimation Of Book Closure Pursuant To Section 91 Of Companies Act,2013 And Regulation 42 Of The SEBI (Lis
-
Unjha Formulatio - Annual General Meeting On 13Th August, 2025
Key fundamentals
Evaluate the intrinsic value of Unjha Formulations Ltd stock
| Name | March-25 | March-24 | March-23 | March-22 | March-21 |
|---|---|---|---|---|---|
| Assets | 3.1387 | 2.7312 | 2.4534 | 2.1708 | 1.9184 |
| Liabilities | 3.1387 | 2.7312 | 2.4534 | 2.1708 | 1.9184 |
| Equity | 4.4805 | 4.4805 | 4.4805 | 4.4805 | 4.4805 |
| Gross Profit | 0.5154 | 0.5758 | 0.4332 | 0.3217 | 0.139 |
| Net Profit | 0.4075 | 0.2779 | 0.2824 | 0.2524 | 0.1035 |
| Cash From Operating Activities | -0.0449 | 1.0261 | -0.3146 | 0.2765 | -0.7029 |
| NPM(%) | 2.93 | 1.5 | 2.14 | 1.78 | 1.04 |
| Revenue | 13.8621 | 18.496 | 13.1537 | 14.1639 | 9.9552 |
| Expenses | 13.3467 | 17.9202 | 12.7205 | 13.8422 | 9.8161 |
| ROE(%) | 12.98 | 8.85 | 8.99 | 8.04 | 3.29 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Unjha Formulations Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 806.00 | -0.44 | 73.18 | 14.61 | 301.39 | 0.62 |
| Lotus Eye Hospital and Institute Ltd | 101.47 | 3.89 | 328.81 | 53.24 | 3.55 | 0.00 |
| Bharat Immunological and Biologicals Corporation Ltd | 22.62 | -0.04 | 0.00 | 110.54 | -39.50 | 0.00 |
| Astec Lifesciences Ltd | 857.05 | -5.15 | 0.00 | 50.21 | -604.77 | 0.00 |
Company Info
M/s. Unjha Formulations Limited was established in June 1987 as a partnership firm for manufacturing Pharmaceutical Formulations at Khali Char Rasta, Tal: Sidhpur, Dist: Mehsana. The firm has now been converted into a Public Limited Company vide Certificate of Incorporation No.04/22932 of 1994-95 dated 2.9.94. The company is presently manufacturing pharmaceutical formulations like liquids, powder, tablets, capsules, injectibles etc. The Company is one of the largest manufacturers of Isabgul products in India. The company is located in the heart of Isabgul growing region, worldwide. The Company has seen uninterrupted growth since incorporation and the sales have consistently risen from Rs.85 lacs in 1991-92 to Rs.348.50 lacs in 1994-95. The Company is presently manufacturing an extensive range of Pharmaceutical Formulations for human consumption and for veteniary use. The sales therefore are divided into the two segments viz: human consumption and veterinary products. In the proposed expansion programme, the company proposes to manufacture additional tablets and injectibles for human consumption and also catering veterinary market. The company has identified the market segment for veterinary drugs as a less competitive market. Other Companies promoted by the promoter are in the business of procuring and trading in Psyllium husk. The Company procures this processed husk for its various products. Therefore, there is no conflict of interest. Also not all the raw material is procured from companies promoted by the same promoters and procurement is based on best rates available. "Gelax" is one of the main products of the company, catering to the domestic market. The Company has signed a MOU with the Indian Immunological Hyderabad (a unit of the National Dairy Development Board) for the offtake of their products. The Company has seen its exports continuously increase from Rs.5.52 lacs in 1991-92 to Rs.38.56 lacs in 1994-95. The company has received Export Orders from Companies in Kenya, and Dubai for Magnesium Silicate Compound and Isabgul Products, worth Rs.46.10 lacs. The Company is operating in an industry where there are major pharmaceutical companies - both Indian and Multinational - operating. However the company has an inherent advantage in that it is located in the heart of the Isabgul growing regions in the world with promoters well experienced in the procurement of Psyllium Husk - the major raw material for the company's products. Also it has firm marketing tie up with a major concern which has a strong brand image. 2007 E-mail ID for Investor Complaints :unjfor@sancharnet.in
M/s. Unjha Formulations Limited was established in June 1987 as a partnership firm for manufacturing Pharmaceutical Formulations at Khali Char Rasta, Tal: Sidhpur, Dist: Mehsana. The firm has now been converted into a Public Limited Company vide Certificate of Incorporation No.04/22932 of 1994-95 dated 2.9.94. The company is presently manufacturing pharmaceutical formulations like liquids, powder, tablets, capsules, injectibles etc. The Company is one of the largest manufacturers of Isabgul products in India. The company is located in the heart of Isabgul growing region, worldwide. The Company has seen uninterrupted growth since incorporation and the sales have consistently risen from Rs.85 lacs in 1991-92 to Rs.348.50 lacs in 1994-95. The Company is presently manufacturing an extensive range of Pharmaceutical Formulations for human consumption and for veteniary use. The sales therefore are divided into the two segments viz: human consumption and veterinary products. In the proposed expansion programme, the company proposes to manufacture additional tablets and injectibles for human consumption and also catering veterinary market. The company has identified the market segment for veterinary drugs as a less competitive market. Other Companies promoted by the promoter are in the business of procuring and trading in Psyllium husk. The Company procures this processed husk for its various products. Therefore, there is no conflict of interest. Also not all the raw material is procured from companies promoted by the same promoters and procurement is based on best rates available. "Gelax" is one of the main products of the company, catering to the domestic market. The Company has signed a MOU with the Indian Immunological Hyderabad (a unit of the National Dairy Development Board) for the offtake of their products. The Company has seen its exports continuously increase from Rs.5.52 lacs in 1991-92 to Rs.38.56 lacs in 1994-95. The company has received Export Orders from Companies in Kenya, and Dubai for Magnesium Silicate Compound and Isabgul Products, worth Rs.46.10 lacs. The Company is operating in an industry where there are major pharmaceutical companies - both Indian and Multinational - operating. However the company has an inherent advantage in that it is located in the heart of the Isabgul growing regions in the world with promoters well experienced in the procurement of Psyllium Husk - the major raw material for the company's products. Also it has firm marketing tie up with a major concern which has a strong brand image. 2007 E-mail ID for Investor Complaints :unjfor@sancharnet.in
Read More
Parent Organisation
Unjha Formulations Ltd.
Founded
02/09/1994
Managing Director
Mrs.Krutiben M Patel
NSE Symbol
FAQ
The current price of Unjha Formulations Ltd is
The 52-week high for Unjha Formulations Ltd is
The market capitalization of Unjha Formulations Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Unjha Formulations Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Unjha Formulations Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Unjha Formulations Ltd shares.
The CEO of Unjha Formulations Ltd is Mrs.Krutiben M Patel, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
